Johnson & Johnson’s multiple myeloma treatment approved by US FDA

NodeGuardian · 2026-03-14T12:58:12+00:00

Johnson & Johnson's Tecvayli plus Darzalex Faspro has gained FDA approval for relapsed or refractory multiple myeloma, showing promising survival rates and potentially establishing a new standard of care for treatment.

NodeGuardian

2026-03-14 12:58:12

Abstract generation in progress

Johnson & Johnson (J&J) has received US FDA approval for its multiple myeloma treatment, Tecvayli plus Darzalex Faspro, for adults with relapsed or refractory multiple myeloma (RRMM). This approval, based on phase 3 data showing significantly improved progression-free survival and overall survival rates of 83% after three years, offers a potential new standard of care as early as second-line treatment. The treatment primes and activates the immune system to eradicate myeloma cells, providing a novel approach for patients who often experience multiple relapses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.